LGNXZ — LIGAND PHARMACEUTICALS INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 886163 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 45,333,000 | 37,076,000 | -36,216,000 | -42,451,000 | 1,560,637,000 | 174,927,000 | 543,425,000 |
| Dec 2024 | 51,812,000 | 43,554,000 | 3,143,000 | -7,172,000 | 941,774,000 | 72,307,000 | 111,335,000 |
| Dec 2023 | 32,868,000 | 24,630,000 | 3,078,000 | -10,273,000 | 787,216,000 | 22,954,000 | 86,303,000 |
| Dec 2022 | 59,221,000 | 50,653,000 | 12,341,000 | 404,000 | 762,668,000 | 45,006,000 | 165,183,000 |
Yahoo Snapshot (yfinance, live)
Total Revenue
$290,542,016
EBITDA
$133,011,000
Free Cash Flow
$139,748,880
Enterprise Value
—
Total Cash
$1,357,757,952
Total Debt
$1,131,453,056
Shares Out
—
Trailing EPS
—
Book Value
$48.57
ROE
22.0%
ROA
4.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 10y)
Revenues vs Net Income (last 10y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2024 | 131,314,000 | 11,942,000 | 52,154,000 | 941,774,000 | 111,335,000 | 830,439,000 | — |
| Dec 2023 | 196,245,000 | 3,037,000 | -33,361,000 | 787,216,000 | 86,303,000 | 700,913,000 | — |
| Dec 2022 | 241,544,000 | 103,851,000 | 57,138,000 | 762,668,000 | 165,183,000 | 597,485,000 | — |
| Dec 2021 | 46,592,000 | -10,144,000 | 18,107,000 | 1,297,590,000 | 476,431,000 | 821,159,000 | — |
| Dec 2020 | 120,282,000 | 807,076,000 | 629,302,000 | 1,362,285,000 | 652,760,000 | 709,525,000 | — |
| Dec 2019 | 43,484,000 | 13,746,000 | 666,337,000 | 1,494,915,000 | 727,683,000 | 767,232,000 | — |
| Dec 2018 | 56,157,000 | 37,041,000 | 45,279,000 | 1,260,803,000 | 699,889,000 | 560,914,000 | — |
| Dec 2017 | 56,157,000 | 37,041,000 | 45,279,000 | 671,021,000 | 252,374,000 | 399,788,000 | — |
| Dec 2016 | 29,648,000 | 15,096,000 | 6,608,000 | 601,585,000 | 230,732,000 | 341,290,000 | — |
| Dec 2015 | 14,602,000 | 3,349,000 | 754,000 | 503,061,000 | 226,151,000 | 237,282,000 | — |
TTM Snapshot
Revenues TTM
$189,234,000
NetIncome TTM
$-59,492,000
OpCashFlow TTM
$0
Assets (Latest)
$1,560,637,000
Forward EPS
—
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.06T | $1183.46 | — |
| JNJ | JOHNSON & JOHNSON | $653.61B | $271.22 | — |
| ABBV | AbbVie Inc. | $467.12B | $264.34 | — |
| MRK | Merck & Co., Inc. | $367.07B | $148.78 | — |
| NVS | NOVARTIS AG | $276.48B | $145.46 | — |
News headlines (Yahoo Finance, 1h cache)
Ligand (LGND)-AvenCell Deal: Most of the Funding Is Tied to Milestones
2026-09-27 13:08 · Yahoo
Twilio downgraded, Synopsys upgraded: Wall Street's top analyst calls
2026-09-25 13:43 · Yahoo
Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million
2026-09-24 11:00 · Yahoo
Sydnexis Announces Royalty Agreement with Ligand for Ryjunea®
2026-09-22 13:02 · Yahoo
Primrose Bio® Raises Significant Growth Capital Investment Led by Signet Healthcare Partners
2026-09-22 13:00 · Yahoo
Ligand Acquires Royalty and Milestone Interest in Santen’s Ryjunea® from Sydnexis for $23 Million
2026-09-22 11:00 · Yahoo
Ligand Pharmaceuticals (LGND): Massive XOMA Acquisition Doubles The Royalty Book
2026-09-04 10:44 · Yahoo
Ligand Pharmaceuticals Highlights XOMA-Fueled Royalty Growth, $700M in Deployable Capital
2026-08-26 17:02 · Yahoo
Ligand to Participate in September Investor Conferences
2026-08-26 11:00 · Yahoo
Breakout Watch: Savvy Investors Bet Millions On Royalty-Fueled Pharma Stock
2026-08-14 20:02 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.